Your browser doesn't support javascript.
loading
Piloting a surveillance system for HIV drug resistance in the European Union.
van de Laar, Marita Jw; Bosman, Arnold; Pharris, Anastasia; Andersson, Emmi; Assoumou, Lambert; Ay, Eva; Bannert, Norbert; Bartmeyer, Barbara; Brady, Melissa; Chaix, Marie-Laure; Descamps, Diane; Dauwe, Kenny; Fonager, Jannik; Hauser, Andrea; Lunar, Maja; Mezei, Maria; Neary, Martha; Poljak, Mario; van Sighem, Ard; Verhofstede, Chris; Amato-Gauci, Andrew J; Broberg, Eeva K.
Afiliação
  • van de Laar MJ; MJW van de Laar Consultancy, Zennewijnen, The Netherlands.
  • Bosman A; Transmissible, Houten, The Netherlands.
  • Pharris A; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
  • Andersson E; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
  • Assoumou L; Department of Clinical Microbiology, Karolinska University Laboratory, Stockholm, Sweden.
  • Ay E; INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
  • Bannert N; National Public Health Institute, Department of Retroviruses, Budapest, Hungary.
  • Bartmeyer B; Robert Koch Institute, Berlin, Germany.
  • Brady M; Robert Koch Institute, Berlin, Germany.
  • Chaix ML; Health Service Executive (HSE), Health Protection Surveillance Centre, Dublin, Ireland.
  • Descamps D; Laboratoire de Virologie, APHP, Saint Louis Hospital, INSERM UMR944, Paris, France.
  • Dauwe K; Paris Diderot University, Paris, France.
  • Fonager J; Paris Diderot University, Paris, France.
  • Hauser A; Laboratoire de Virologie, Bichat-Claude Bernard University Hospital, INSERM UMR_1137, Paris, France.
  • Lunar M; Aids Reference Laboratory, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
  • Mezei M; Virus and Microbiological Special Diagnostics, Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark.
  • Neary M; Robert Koch Institute, Berlin, Germany.
  • Poljak M; Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • van Sighem A; National Public Health Institute, Department of Retroviruses, Budapest, Hungary.
  • Verhofstede C; University College Dublin (UCD), National Virus Reference Laboratory, Dublin, Ireland.
  • Amato-Gauci AJ; Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Broberg EK; Stichting HIV Monitoring, Amsterdam, The Netherlands.
Euro Surveill ; 24(19)2019 May.
Article em En | MEDLINE | ID: mdl-31088600
BackgroundA steady increase in HIV drug resistance (HIVDR) has been demonstrated globally in individuals initiating first-line antiretroviral therapy (ART). To support effective use of ART and prevent spread of HIVDR, monitoring is essential.AimWe piloted a surveillance system for transmitted HIVDR to assess the feasibility of implementation at the European level.MethodAll 31 countries in the European Union and European Economic Area were invited to retrospectively submit data on individuals newly diagnosed with HIV in 2015 who were tested for antiviral susceptibility before ART, either as case-based or as aggregate data. We used the Stanford HIV database algorithm to translate genetic sequences into levels of drug resistance.ResultsNine countries participated, with six reporting case-based data on 1,680 individuals and four reporting aggregated data on 1,402 cases. Sequence data were available for 1,417 cases: 14.5% of individuals (n = 244) showed resistance to at least one antiretroviral drug. In case-based surveillance, the highest levels of transmitted HIVDR were observed for non-nucleoside reverse-transcriptase inhibitors (NNRTIs) with resistance detected in 8.6% (n = 145), followed by resistance to nucleoside reverse-transcriptase inhibitors (NRTI) (5.1%; n = 85) and protease inhibitors (2.0%; n = 34).ConclusionWe conclude that standard reporting of HIVDR data was feasible in the participating countries. Legal barriers for data sharing, consensus on definitions and standardisation of interpretation algorithms should be clarified in the process of enhancing European-wide HIV surveillance with drug resistance information.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV / Farmacorresistência Viral Tipo de estudo: Prevalence_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Euro Surveill Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV / Farmacorresistência Viral Tipo de estudo: Prevalence_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Euro Surveill Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Holanda